Exploring how tumor microenvironment changes affect treatment for esophageal cancer
Official title: Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Run by Renmin Hospital of Wuhan University · NCT05894369 · Data updated 2026-11-12
This study is testing how changes in inflammation and the tumor environment affect the success of treatment for patients with esophageal cancer who are receiving chemotherapy and immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Renmin Hospital of Wuhan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | May 4, 2023 |
| Main results expected | June 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | November 25, 2024 |
| Trial ID | NCT05894369 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 80 with a confirmed diagnosis of esophageal squamous cell carcinoma at clinical stages II-IVA who are eligible for neoadjuvant therapy.
✕Probably not a fit
Patients with a life expectancy of less than 6 months, those with distant metastasis at diagnosis, or individuals with other significant health issues may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the role of inflammatory factors in the blood and their predictive value on the prognosis of patients with esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy combined with immunotherapy. It aims to collect baseline patient information and laboratory data before and during treatment to understand how inflammation and the tumor microenvironment influence treatment efficacy. The study will involve patients admitted to Hubei Provincial People's Hospital from May 2023 to December 2024, with a target enrollment of 60 participants.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with esophageal cancer, enhancing their overall survival rates.
How similar studies have gone: While this approach is exploring new mechanisms, similar studies have shown promise in understanding the tumor microenvironment's impact on treatment outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria： The patient's age between 18 to 80 years old; Esophageal squamous cell carcinoma with definite pathological diagnosis and II-IVA clinical stage Preoperative neoadjuvant chemotherapy combined with immunotherapy The score of eastern cooperative oncology group is 0 \~ 1 Exclusion criteria The estimated survival time is less than 6 months; The first diagnosis had distant metastasis Suffering from malignant tumor or accompanying malignant disease in the past 5 years Pregnant or pregnant women. Vulnerable groups (those without informed ability, minors, vagrants, students and subordinates of researchers, employees of bidders)
Where it's running
-
Renmin hosptial of Wuhan University
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Yong Shun Chen
- Email: yongshun2007@163.com
- Phone: 86+153 2712 2084
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PF-08098488 in adults with advanced solid tumors
This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.
-
Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.
-
MGC030 in adults with advanced solid tumors
This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.